Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 65 out of 100. How common it is

Topic: Amyloid, tau and blood-test diagnosis

Objective Whereas cognitive deficits are known to be detectable long before the typical symptoms of Alzheimer's disease (AD) are evident, previous studies have failed to determine when cognitive functioning actually begins to decline before dementia. Utilizing the long follow-up of the PAQUID study, we examined the emergence of the first clinical symptoms over a 14-year period of follow-up before the dementia phase of AD. Methods This study relies on a case-control sample selected from the PAQUID cohort. Of the 3,777 initial subjects of the cohort, 350 subjects experienced development of AD during the 14 years of follow-up. The cases were matched to 350 elderly control subjects. The evolution of scores on cognitive, functional, and depression scales was described throughout the 14-year follow-up using a semiparametric extension of the mixed-effects linear model. Results The first decline in cognitive performances appeared as early as 12 years before dementia in measures of semantic memory and conceptual formation. Then, more global deficits appeared that were concomitant with an increase in memory complaints and depressive symptoms. About 2 years later, as a consequence of cognitive dysfunction, the subjects started to become slightly dependent in their activities of daily living. In the last 3 years, the impairment significantly worsened until the subjects reached the dementia phase. Interpretation This approach, describing the 14 years preceding dementia, provides a clear illustration of the particularly long and progressive prodromal phase of AD, and shows the successive emergence of cognitive deficits, depressive symptoms, and functional impairment during this phase.

Key findings

Why it matters

In 350 people from the PAQUID cohort who developed Alzheimer's over 14 years, compared with 350 matched older adults who did not, the first measurable decline appeared "as early as 12 years before dementia" in semantic memory and conceptual formation. The study describes broader thinking problems emerging next, alongside more memory complaints and depressive symptoms, then slight dependence in daily activities about 2 years later, and a marked worsening in the final 3 years before diagnosis. This maps the order in which symptoms emerged on average in this group. It does not predict who will develop dementia, and it tested no treatment.

Study details

How this study scored 65/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 3 of 4; Study design 6 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited 6 of 7; Citations per year 4 of 5; Impact for its field and year 4 of 6; Cited by studies here 4 of 6; Still being cited 3 of 4; Senior author's track record 2 of 4; Institution's track record 2 of 3; Multi-centre collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 65 of 100.65 of 100 points earned35 not earned

Published in a leading specialty journal, and it is a case-control study. Scored zero for effect reported and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Annals of neurology)
Journal's citation record 3 / 4 Annals of Neurology: journal h-index 437 (OpenAlex, 2026-10-29)
Study design 6 / 12 A case-control study
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2008 — within 20 year(s) of the newest study here
Sample size 2 / 4 350 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 6 / 7 Cited 738 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 36.9 citations a year over 20 year(s) since 2008
Impact for its field and year 4 / 6 Cited 19.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 4 / 6 Cited by 41 other studies in this library
Still being cited 3 / 4 Cited 86 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Jean François Dartigues: h-index 31 (OpenAlex, whole career)
Institution's track record 2 / 3 Inserm: institution h-index 1,988 (OpenAlex)
Multi-centre collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 19067364)
Free to read 0 / 2 Behind a paywall — scores zero
Total 65 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

APA 7th

Amieva, H., Le Goff, M., Millet, X., Orgogozo, J. M., Pérès, K., Barberger-Gateau, P., et al. (2008). Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. Annals of neurology. https://doi.org/10.1002/ana.21509

Vancouver

Amieva H, Le Goff M, Millet X, Orgogozo JM, Pérès K, Barberger-Gateau P, et al. Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. Annals of neurology. 2008. doi:10.1002/ana.21509. PMID: 19067364.

BibTeX

@article{amieva2008-19067364,
  author  = {Amieva, H. and Le Goff, M. and Millet, X. and Orgogozo, J. M. and Pérès, K. and Barberger-Gateau, P. and Jacqmin-Gadda, H. and Dartigues, J. F.},
  title   = {{Prodromal Alzheimer's disease: successive emergence of the clinical symptoms}},
  journal = {Annals of neurology},
  year    = {2008},
  doi     = {10.1002/ana.21509},
  pmid    = {19067364},
  url     = {https://doi.org/10.1002/ana.21509}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 18.

Later studies that cite this one

41 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in How common it is

Also in How common it is

80 studies in the library are filed under How common it is with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The How common it is hub.

Similar studies

More on How common it is

See all studies in How common it is →